Company Overview
Genprex, Inc. operates as a clinical-stage gene therapy company dedicated to the development of advanced therapeutic solutions for patients suffering from cancer and diabetes. The firm's technological platform is specifically engineered to facilitate the administration of disease-fighting genes, thereby creating novel treatment pathways for these distinct patient populations. Operating within the Healthcare sector and the Biotechnology industry, the company functions in a high-risk, high-reward environment characterized by rigorous regulatory requirements and significant capital intensity. The entity currently maintains a market capitalization of $2.97M and employs 13 individuals, reflecting a very small-scale operation typical of early-stage biotechnology ventures. These valuation and operational metrics indicate that Genprex is a micro-cap entity with limited market presence, suggesting it is primarily in the research and development phase rather than the commercialization stage where revenue generation typically occurs.
Financial Health
The company reports a Net Income of $-16,769,203 and an EBITDA of $-16,327,233 over the trailing twelve months, while Revenue remains unavailable, a common characteristic for clinical-stage firms before commercial product launch. The substantial negative gap between revenue and net income, coupled with the absence of reported revenue, reveals a cost structure dominated by research and development expenditures rather than cost of goods sold. Free cash flow stands at $-10,176,745, which signifies that the company is consuming cash reserves to fund its operations and clinical trials, indicating a lack of current financial flexibility for self-sustaining growth without external capital. All three margin metrics are reported as 0.0%, specifically the Gross Margin, Operating Margin, and Profit Margin; these figures indicate that the company has not yet achieved profitable operations or recognized significant revenue to calculate traditional margins. The balance sheet shows a Cash position of $1.10M with Debt listed as N/A, implying the company holds its remaining liquidity in cash rather than taking on leverage. Although the Debt to Equity ratio is N/A due to the lack of debt data, the company's financial posture appears un-leveraged but highly reliant on its cash pile to survive. The Current Ratio is 0.67, which indicates that the company's current assets are insufficient to cover its current liabilities without liquidating non-current assets or obtaining new financing. Return on Equity is -1401.4% and Return on Assets is -273.3%, metrics that reveal management is currently burning capital to pursue clinical objectives rather than generating returns for shareholders or efficiently utilizing its asset base.
Valuation Assessment
The Trailing Twelve Months P/E Ratio is N/A because the company is not currently profitable, while the Forward P/E is -0.83, a metric that is often difficult to interpret for loss-making biotechnology companies and implies negative expected earnings in the immediate future. The Price to Book ratio is 2.38, suggesting that the market values the company at 2.38 times its book value, which may reflect the potential intrinsic value of its intellectual property and pipeline despite current losses. The Price to Sales ratio is N/A and the EV/EBITDA is -0.19, indicating that traditional sales-based or earnings-based valuation multiples are not applicable, and the negative EV/EBITDA further underscores the firm's negative earnings power. The stock has a 52-Week High of $55.00 and a 52-Week Low of $1.71, creating a massive volatility range where the current price sits significantly closer to the low end of the spectrum. The Beta is -0.72, a highly unusual negative value that suggests the stock price tends to move inversely to the broader market, presenting a unique risk profile for investors seeking correlation with market trends.
Growth & Income
Revenue Growth Year over Year and Earnings Growth Year over Year are both N/A, as the company has not yet generated sustained commercial revenue or reported comparable earnings periods to establish a growth trajectory. Since the company is a non-dividend payer, it does not distribute a Dividend Yield or a Payout Ratio, meaning the 0.0% payout ratio reflects a strategy of reinvesting all available resources back into the business rather than distributing income to shareholders. This approach is standard for clinical-stage biotechnology firms that must allocate capital toward advancing their oncology and diabetes programs through clinical trials. The overall growth and income profile is defined entirely by the potential future success of the clinical pipeline, as current financial statements show no historical income generation or dividend distribution history.